Mirati Therapeutics initiated with a Neutral at Cantor Fitzgerald. Cantor Fitzgerald analyst Varun Kumar last night started Mirati Therapeutics with a Neutral rating and $66 price target. Current consensus estimates reflect high expectations around the novel KRASi asset, and do not fully appreciate potential clinical, regulatory and commercial risks associated with the company’s lead asset sitravatinib, Kumar tells investors in a research note.
https://thefly.com/landingPageNews.php?id=2874251
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.